Trailhead Biosystems® Expands Human Cell-Based Product Line with iPSC-Derived A9 Dopaminergic Neurons
A9 dopaminergic neurons play a critical role in movement regulation and are disproportionately affected in Parkinson's disease. Historically, researchers have lacked access to viable human models, relying instead on animal studies with limited relevance. With TrailBio® A9 Dopaminergic Neurons, scientists now have a human-specific platform to investigate disease mechanisms, develop therapies and accelerate drug discovery.
"TrailBio® A9 Dopaminergic Neurons open new possibilities for Parkinson's research," said Dr. Jan Jensen, Chief Scientific Officer, Chief Technology Officer and founder of Trailhead Biosystems. "These cells enable researchers to study the vulnerabilities of A9 neurons, helping drive progress toward more effective treatments."
"For decades, the lack of human A9 neurons has limited our ability to truly understand Parkinson's disease," added Dr. Nooshin Amini, Scientific Director at Trailhead Biosystems. "Now, with TrailBio® A9 Dopaminergic Neurons, researchers can directly study the exact cells that are most affected, offering hope for groundbreaking insights and future therapies."
About Trailhead Biosystems
Trailhead Biosystems, Inc. is pioneering an informatics-based approach in regenerative medicine and drug discovery. Founded in 2015 as a spinout from the Cleveland Clinic and Case Western Reserve University, Trailhead emerged from the research of CSO/CTO and founder Dr. Jan Jensen. Trailhead creates optimized human cells at scale with its proprietary High-Dimensional Design-of-Experiments (HD-DoE®) platform, integrating advanced mathematical modeling with high-throughput robotic manufacturing. This innovative system allows Trailhead to develop specialized, high-quality iPSC-derived human cells for drug discovery and cell-based therapies. TrailBio® A9 Dopaminergic Neurons represent one of many specialized human cell types emerging from this platform, with additional cell models expected in the near future.
Learn more about Trailhead Biosystems, TrailBio® A9 Dopaminergic Neurons and HD-DoE® at www.TrailBio.com.
For more information, please contact:
Tim Mauk, Corporate CommunicationsTrailhead BiosystemsEmail: info@trailbio.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/trailhead-biosystems-expands-human-cell-based-product-line-with-ipsc-derived-a9-dopaminergic-neurons-302511153.html
SOURCE Trailhead Biosystems Inc
View original content to download multimedia: http://www.newswire.ca/en/releases/archive/July2025/23/c9844.html
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 minutes ago
- Yahoo
US, China to launch new talks on tariff truce extension, easing path for Trump-Xi meeting
By David Lawder STOCKHOLM (Reuters) -Top U.S. and Chinese economic officials will resume talks in Stockholm on Monday to try to tackle longstanding economic disputes at the centre of a trade war between the world's top two economies, aiming to extend a truce by three months and keeping sharply higher tariffs at bay. China is facing an August 12 deadline to reach a durable tariff agreement with President Donald Trump's administration, after Beijing and Washington reached preliminary deals in May and June to end weeks of escalating tit-for-tat tariffs and a cut-off of rare earth minerals. Without an agreement, global supply chains could face renewed turmoil from U.S. duties snapping back to triple-digit levels that would amount to a bilateral trade embargo. The Stockholm talks come hot on the heels of Trump's biggest trade deal yet with the European Union on Sunday for a 15% tariff on most EU goods exports to the U.S., including autos. The bloc will also buy $750 billion worth of American energy and make $600 billion worth of U.S. investments in coming years. No similar breakthrough is expected in the U.S.-China talks but trade analysts said that another 90-day extension of a tariff and export control truce struck in mid-May was likely. An extension of that length would prevent further escalation and facilitate planning for a potential meeting between Trump and Chinese President Xi Jinping in late October or early November. A U.S. Treasury spokesperson declined comment on a South China Morning Post report quoting unnamed sources as saying the two sides would refrain from introducing new tariffs or other steps that could escalate the trade war for another 90 days. Trump's administration is poised to impose new sectoral tariffs that will impact China within weeks, including on semiconductors, pharmaceuticals, ship-to-shore cranes and other products. "We're very close to a deal with China. We really sort of made a deal with China, but we'll see how that goes," Trump told reporters on Sunday before European Commission President Ursula von der Leyen struck their tariff deal. DEEPER ISSUES Previous U.S.-China trade talks in Geneva and London in May and June focused on bringing U.S. and Chinese retaliatory tariffs down from triple-digit levels and restoring the flow of rare earth minerals halted by China and Nvidia's H20 AI chips and other goods halted by the United States. So far, the talks have not delved into broader economic issues. They include U.S. complaints that China's state-led, export-driven model is flooding world markets with cheap goods, and Beijing's complaints that U.S. national security export controls on tech goods seek to stunt Chinese growth. "Geneva and London were really just about trying to get the relationship back on track so that they could, at some point, actually negotiate about the issues which animate the disagreement between the countries in the first place," said Scott Kennedy, a China economics expert at the Center for Strategic and International Studies in Washington. "I'd be surprised if there is an early harvest on some of these things but an extension of the ceasefire for another 90 days seems to be the most likely outcome," Kennedy said. U.S. Treasury Secretary Scott Bessent has already flagged a deadline extension and has said he wants China to rebalance its economy away from exports to more domestic consumption -- a decades-long goal for U.S. policymakers. Analysts say the U.S.-China negotiations are far more complex than those with other Asian countries and will require more time. China's grip on the global market for rare earth minerals and magnets, used in everything from military hardware to car windshield wiper motors, has proved to be an effective leverage point on U.S. industries. TRUMP-XI MEETING? In the background of the talks is speculation about a possible meeting between Trump and Xi in late October. Trump has said he will decide soon on a landmark trip to China, and a new flare-up of tariffs and export controls would likely derail planning. Sun Chenghao, a fellow at Tsinghua University's Center for International Security and Strategy in Beijing, said that a Trump-Xi summit would be an opportunity for the U.S. to lower the 20% tariffs on Chinese goods related to fentanyl. In exchange, he said the Chinese side could make good on its 2020 pledge to increase purchases of U.S. farm products and other goods. "The future prospect of the heads of state summit is very beneficial to the negotiations because everyone wants to reach an agreement or pave the way in advance," Sun said. Still, China will likely request a reduction of multi-layered U.S. tariffs totaling 55% on most goods and further easing of U.S. high-tech export controls, analysts said. Beijing has argued that such purchases would help reduce the U.S. trade deficit with China, which reached $295.5 billion in 2024.
Yahoo
5 minutes ago
- Yahoo
Hong Kong's CK Hutchison seeks Chinese investor to join Panama Ports deal
HONG KONG (AP) — A Hong Kong conglomerate that's selling ports at the Panama Canal said Monday it may seek a Chinese investor to join a consortium of buyers, a move that could please Beijing but bring more U.S. scrutiny to the geopolitically fraught deal. CK Hutchison Holdings' initial plan to sell its port assets to a group that includes U.S. investment firm BlackRock Inc. pleased President Donald Trump, who has alleged that China interferes with the critical shipping lane's operations in Panama. However, they apparently angered Beijing and drew a review from Chinese anti-monopoly authorities. A Beijing-backed newspaper posted scathing commentaries about the deal, with one describing it as a betrayal of all Chinese. Beijing's offices overseeing Hong Kong affairs have reposted some of these commentaries, widely seen as an indication of Chinese leaders' stance. A Hutchison subsidiary has operated ports at both ends of the Panama Canal since 1997. After months of uncertainty brought by tensions between Washington and Beijing, Hutchison said in a statement that the exclusive negotiations period with the consortium has expired. However, it added 'the Group remains in discussions with members of the consortium with a view to inviting major strategic investor from the PRC to join as a significant member of the consortium,' referring to the People's Republic of China. It said they needed to change the membership of the consortium and the structure of the transaction for the deal to be able to pass reviews by 'all relevant authorities." The awkward position Hutchison found itself in for months highlights the challenges Hong Kong business elites face in navigating Beijing's expectations of national loyalty, especially when relations between China and the United States are strained. Hong Kong has overhauled its electoral system to ensure the city is run by 'patriots.' CK Hutchison is owned by the family of Hong Kong's richest man, Li Ka-shing. It announced March 4 that it would sell all its shares in Hutchison Port Holdings and in Hutchison Port Group Holdings to the consortium that also includes BlackRock subsidiary Global Infrastructure Partners and Terminal Investment Limited, a subsidiary of the Mediterranean Shipping Company. In May, Hutchinson co-managing director, Dominic Lai told shareholders that Terminal Investment was the main investor. Its parent company is led by Italian shipping scion Diego Aponte, whose family reportedly has a longstanding relationship with Li's. The initial deal, valued at nearly $23 billion including $5 billion in debt, would have given the consortium control over 43 ports in 23 countries, including the ports of Balboa and Cristobal, located at either end of the canal. That agreement also required approval from Panama's government. The deadline for their exclusive negotiation period ended on July 27. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Bloomberg
7 minutes ago
- Bloomberg
Brookfield, Birch Hill Snag Canadian Mortgage Firm in $2.1 Billion Deal
Brookfield Asset Management and a private equity partner reached a friendly deal to take over First National Financial Corp., a mortgage company backed by Canadian billionaire Stephen Smith, for about C$2.9 billion ($2.1 billion). Funds managed by Brookfield and Toronto-based Birch Hill Equity Partners Management Inc. agreed to pay C$48 a share in cash for First National, an originator of commercial and residential mortgages. That's a 13% premium to where the shares closed Friday.
